ReviewFuture microbiology2014
Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease.
Review in Future microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
211 citing papers in PubMed, 410 citations in OpenAlex.
- Co-incubation of Bacillus spp. alleviated the growth and gas production of potentially harmful bacteria in different in vitro methodologies.JDS communications · 2026Article
- Innovative Approaches Against Planktonic and Biofilm-ProducingVeterinary sciences · 2026Review
- Epidemiological and Metabolic Characteristics ofAnimals : an open access journal from MDPI · 2026Article
- Seasonal Prevalence, Molecular Identification and Therapeutic Management of Enterotoxemia Caused by Clostridium perfringens Type D in Goats of Peshawar and Charsadda Districts, Pakistan.Veterinary medicine and science · 2026Article
- Identification and Genomic Localization of theMicroorganisms · 2026Article
- Wastewater reuse for production of plant-based foods: does spore-formingApplied and environmental microbiology · 2026Review
- Molecular epidemiology and PFGE-based genetic diversity of Clostridium perfringens in broiler chickens from Eastern Türkiye.BMC veterinary research · 2026Article
- Impact of extraction method on the chemical composition and antibacterial potential of Salvia fruticosa essential oil.BMC complementary medicine and therapies · 2026Article
- Article
- Isolation of anaerobic bacteria from bovine mastitis cases in Mombetsu district, Japan.The Journal of veterinary medical science · 2026Article
- A novel typing method forFrontiers in microbiology · 2026Article
- Characterization of Bacterial Communities in Air and Bedding Materials of Intensive Donkey Farms During Summer.Microorganisms · 2025Article
- Genetic diversity and evolutionary adaptation of Clostridium paraputrificum, a rare pathogen in humans.Communications biology · 2025Article
- Garvicin Q-producing Lactococcus garvieae LG3092: its role in mitigating dysbiosis and H. pylori-associated gastritis.NPJ biofilms and microbiomes · 2025Article
- Characteristics of Clostridium perfringens from sheep (Ovis aries) flocks in Northern China.Veterinary research communications · 2025Article
- Structural and dynamic basis of Ssp4-mediated DNA protection in foodborne bacterial spores.Scientific reports · 2025Article
- Genomic and physiochemical characterization of two lysogenic bacteriophages, ΦCP5(17) and ΦCP17(i), infecting Clostridium perfringens.Archives of virology · 2025Article
- Structures of a synthetic antibody selected against and bound to the C-terminal domain of Clostridium perfringens enterotoxin.Protein science : a publication of the Protein Society · 2025Article
- Article
- Epidemiology of potential source, risk attribution of Clostridium perfringens from Egyptian broiler farms and genetic diversity of multidrug resistance strains.Scientific reports · 2025Article
151 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Clostridium perfringens uses its arsenal of >16 toxins to cause histotoxic and intestinal infections in humans and animals. It has been unclear why this bacterium produces so many different toxins, especially since many target the plasma membrane of host cells. However, it is now established that C. perfringens uses chromosomally encoded alpha toxin (a phospholipase C) and perfringolysin O (a pore-forming toxin) during histotoxic infections. In contrast, this bacterium causes intestinal disease by employing toxins encoded by mobile genetic elements, including C. perfringens enterotoxin, necrotic enteritis toxin B-like, epsilon toxin and beta toxin. Like perfringolysin O, the toxins with established roles in intestinal disease form membrane pores. However, the intestinal disease-associated toxins vary in their target specificity, when they are produced (sporulation vs vegetative growth), and in their sensitivity to intestinal proteases. Producing many toxins with diverse characteristics likely imparts virulence flexibility to C. perfringens so it can cause an array of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.